Use of risankizumab in two HIV-positive patients with psoriasis.
作者信息
Maliyar Khalad, Lansang Perla, Doiron Philip
机构信息
Division of Dermatology, University of Toronto, Toronto, Canada.
出版信息
JAAD Case Rep. 2023 Jan 30;33:54-55. doi: 10.1016/j.jdcr.2023.01.015. eCollection 2023 Mar.
Abstract
摘要
相似文献
1
Use of risankizumab in two HIV-positive patients with psoriasis.司库奇尤单抗在两名银屑病 HIV 阳性患者中的应用。
JAAD Case Rep. 2023 Jan 30;33:54-55. doi: 10.1016/j.jdcr.2023.01.015. eCollection 2023 Mar.
2
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.司库奇尤单抗与瑞莎珠单抗治疗中重度银屑病患者的疗效对比：IMMerge研究的亚组分析
Dermatol Ther (Heidelb). 2022 Feb;12(2):561-575. doi: 10.1007/s13555-021-00679-6. Epub 2022 Jan 20.
3
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.利斯库单抗治疗可改善中重度斑块型银屑病患者的长期、持久、绝对的银屑病面积和严重程度指数和健康相关生活质量：一项事后综合分析。
J Eur Acad Dermatol Venereol. 2022 Jun;36(6):855-865. doi: 10.1111/jdv.18010. Epub 2022 Mar 17.
4
Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic.司库奇尤单抗治疗中重度银屑病：来自捷克共和国的真实多中心经验。
Dermatol Ther (Heidelb). 2021 Aug;11(4):1345-1355. doi: 10.1007/s13555-021-00556-2. Epub 2021 Jun 5.
5
Risankizumab shows high efficacy and maintenance in improvement of response until week 52.里沙鲁单抗显示出高疗效，并在第 52 周持续改善应答。
Dermatol Ther. 2022 May;35(5):e15378. doi: 10.1111/dth.15378. Epub 2022 Feb 28.
6
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study.利纳西珠单抗治疗中重度斑块状银屑病的真实世界疗效和安全性：一项 40 周的多中心回顾性研究。
Acta Derm Venereol. 2021 Nov 30;101(11):adv00605. doi: 10.2340/actadv.v101.283.
7
Meta-Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority.利纳西珠单抗和阿达木单抗治疗慢性斑块型银屑病的临床疗效的荟萃分析：利纳西珠单抗优势的支持证据。
Clin Pharmacol Ther. 2020 Feb;107(2):435-442. doi: 10.1002/cpt.1624. Epub 2019 Nov 8.
8
Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis.使用机器学习评估 PASI 应答对中重度斑块状银屑病患者工作生产力的影响，以及 risankizumab 对间接成本的影响。
J Dermatolog Treat. 2022 Jun;33(4):2094-2101. doi: 10.1080/09546634.2021.1919287. Epub 2022 Feb 16.
9
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.在中重度斑块型银屑病患者中，连续 risankizumab 治疗与停药治疗的疗效和安全性：一项 3 期随机临床试验。
JAMA Dermatol. 2020 Jun 1;156(6):649-658. doi: 10.1001/jamadermatol.2020.0723.
10
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.基于基线人口统计学、疾病特征和既往生物治疗的疗效：III 期 UltIMMa-1 和 UltIMMa-2 研究的综合分析。
J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2830-2838. doi: 10.1111/jdv.16521. Epub 2020 Jul 3.
引用本文的文献
1
Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers.探索古塞库单抗和司库奇尤单抗对HIV阳性患者银屑病的影响：来自四个意大利中心的见解
Australas J Dermatol. 2025 Jun;66(4):215-219. doi: 10.1111/ajd.14467. Epub 2025 Apr 3.
2
Systematic review of biologic use for psoriasis in HIV-positive individuals from 2018 to 2024.2018 年至 2024 年 HIV 阳性个体银屑病生物制剂应用的系统评价。
Arch Dermatol Res. 2024 Nov 13;317(1):14. doi: 10.1007/s00403-024-03395-1.
3
Risankizumab, a therapeutic alternative for psoriasis in people living with HIV.瑞莎珠单抗，一种用于HIV感染者银屑病的治疗选择。
J Int Med Res. 2024 Mar;52(3):3000605241229324. doi: 10.1177/03000605241229324.
本文引用的文献
1
Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review.4例HIV阳性患者的生物治疗：病例系列及文献综述
J Psoriasis Psoriatic Arthritis. 2021 Jan;6(1):19-26. doi: 10.1177/2475530320954279. Epub 2020 Sep 16.
2
Successful treatment of psoriasis with risankizumab in an HIV positive patient with sexually transmitted infection comorbidities.使用司库奇尤单抗成功治疗一名合并性传播感染的HIV阳性银屑病患者。
Dermatol Ther. 2022 Mar;35(3):e15277. doi: 10.1111/dth.15277. Epub 2021 Dec 28.
3
Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review.目前用于银屑病HIV阳性患者的生物疗法：使用格苏单抗的病例报告及综述
Dermatol Online J. 2018 Nov 15;24(11):13030/qt3db748cg.
4
HIV-associated psoriasis: pathogenesis, clinical features, and management.HIV 相关性银屑病：发病机制、临床特征及治疗。
Lancet Infect Dis. 2010 Jul;10(7):470-8. doi: 10.1016/S1473-3099(10)70101-8.
Zotero 插件